The disclosure relates to stable topical pharmaceutical compositions of SHR0302 (also known as ARQ-250). In certain embodiments, pharmaceutical compositions of SHR0302 having a pH of less than about 4.6 have improved stability and do not exhibit crystal formation of the API. In certain embodiments, pharmaceutical compositions of SHR0302 comprising about 20% to about 30% dimethyl sulfoxide (DMSO) have improved stability and do not exhibit crystal formation of the API. The improved formulations of SHR0302 can exhibit acceptable commercial product shelf life and do not exhibit loss of potency of the API after prolonged storage.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

An emulsion-based method for the manufacture of a crystalized spherical agglomerate and/or a pharmaceutical product is provided; and crystalized spherical agglomerates and/or pharmaceutical products manufactured thereby.

Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.

Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.

The invention pertains to an encapsulation system; in particular a 3-phase system comprising an inner, second and outer phase wherein the second phase is gaseous, and wherein the 3-phase system has a lifetime of at least 3 min and the second phase has a diameter of less than 1 mm. An example of such a system is a stable, small antibubble. Also, the invention pertains to methods of making such 3-phase systems, and to use and methods of use thereof. In particular, 3-phase systems according to the invention are stabilized by surface active particles or molecules, such as for instance colloidal particles. The 3-phase systems of the invention can include a variety of other compounds, and can among others be used in pharmaceutical- or food-based applications. In particular, a 3-phase system according to the invention, such as for example an antibubble, may deliver pharmaceutical compounds.

The invention pertains to an encapsulation system; in particular a 3-phase system comprising an inner, second and outer phase wherein the second phase is gaseous, and wherein the 3-phase system has a lifetime of at least 3 min and the second phase has a diameter of less than 1 mm. An example of such a system is a stable, small antibubble. Also, the invention pertains to methods of making such 3-phase systems, and to use and methods of use thereof. In particular, 3-phase systems according to the invention are stabilized by surface active particles or molecules, such as for instance colloidal particles. The 3-phase systems of the invention can include a variety of other compounds, and can among others be used in pharmaceutical- or food-based applications. In particular, a 3-phase system according to the invention, such as for example an antibubble, may deliver pharmaceutical compounds.

The present invention generally relates to microfluidic droplets and, in particular, to multiple emulsion microfluidic droplets. In one set of embodiments, multiple emulsion droplets are provided, where an inner shell of the droplet is relatively thin, compared to the outer shell (or other shells) of the droplet. For instance, in one set of embodiments, the inner droplet has an average thickness of less than about 1000 nm. In some cases, the inner shell may be rigidified, e.g., to form a gel or a polymeric layer. This may be useful, for example, for preventing coalescence of fluids within the microfluidic droplet. Other embodiments of the present invention are generally directed to methods of making such droplets, methods of using such droplets, microfluidic devices for making such droplets, and the like.

The present invention generally relates to microfluidic droplets and, in particular, to multiple emulsion microfluidic droplets. In one set of embodiments, multiple emulsion droplets are provided, where an inner shell of the droplet is relatively thin, compared to the outer shell (or other shells) of the droplet. For instance, in one set of embodiments, the inner droplet has an average thickness of less than about 1000 nm. In some cases, the inner shell may be rigidified, e.g., to form a gel or a polymeric layer. This may be useful, for example, for preventing coalescence of fluids within the microfluidic droplet. Other embodiments of the present invention are generally directed to methods of making such droplets, methods of using such droplets, microfluidic devices for making such droplets, and the like.